French biotech stock soars 34% after new data on experimental medicine
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease,...
Biotech and Pharmaceuticals
Medicare will start covering obesity drugs for the first time. Here's what patients should know
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity...
America can't get enough of protein. The dairy industry can't keep up
Whitebalance.space | E+ | Getty ImagesAmerica's "protein-maxxing" obsession is stressing the dairy industry.Whey protein concentrate, once considered a cheap byproduct...
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in...
Estrogen patches are hard to find, and it may not be resolved any time soon
Woman applying estrogen patch during hormone therapy.Halfpoint Images | Moment | Getty ImagesEstrogen patches are in short supply as demand...
What this biotech's volatile stock price tells you about the weight loss market right now
Shares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher...
Centene to offer buyouts to some employees as health insurer cuts costs
Sheldon Cooper | Lightrocket | Getty ImagesCentene said it offered buyouts to some employees on Monday, as the health insurer...
Drugmakers race to find a place in the next wave of obesity drugs
Drugmakers are only months into introducing GLP-1 pills and navigating huge changes in how patients pay for weight-loss drugs. Even...
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare...
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Jacob Van Naarden is busy. In addition to running Eli Lilly's oncology business, he's now responsible for finding the drugmaker's next...
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled as much 32% after it reported fresh data on its lead asset, a drug...
Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Thomas Fuller | Lightrocket | Getty ImagesReplimune plans to resubmit its melanoma drug to the Food and Drug Administration for...
CDC says American tests positive for Ebola in Africa, risk in the U.S. remains low
A sign sits outside of the Centers for Disease Control and Prevention (CDC) Roybal campus in Atlanta, Georgia, U.S. March...
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
A Biogen facility in Cambridge, Massachusetts.Brian Snyder | ReutersBiogen plans to advance an experimental drug for Alzheimer's disease to late-stage...
Marty Makary resigns as FDA commissioner following industry and White House backlash
Food and Drug Administration Commissioner Marty Makary speaks during an announcement at the Department of Health and Human Services on...
Rare disease families find roadmap to drug development at bootcamps
Developing a new drug can cost a billion dollars and take more than a decade. That makes investing in new...
Wearable patches: How Barrière is trying to disrupt the supplement industry
The supplement industry has seen booming demand over the past few years as consumers increasingly focus on health and wellness.Along...
CVS blows past estimates, hikes outlook as insurance business outperforms
A screen displays the logo and trading information for CVS at the New York Stock Exchange, March 24, 2026.Jeenah Moon...
Novo Nordisk stock jumps 6% after drugmaker hikes forcast as Wegovy pill sales smash forecasts
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark,...
FDA commissioner defends agency's drug approval decisions after wave of backlash
U.S. Food and Drug Administration Commissioner Marty Makary defended himself in a CNBC interview aired Tuesday after months of pressure...
